Published By : MP Advisors Published Date : 2016-08-26 Category : Company Profile Sub Category : C No. of Pages : 31

The release of a new research report on Cellceutix Corporation (OTCQB: CTIX).  Cellceutix is a clinical stage biopharmaceutical company based in Beverly, Massachusetts developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications.

The 31-page report provides an in-depth analysis of the Cellceutix pipeline of drugs in development, intellectual property, key drivers, upcoming milestones and a sum of parts valuation.  The report takes a detailed look at development and clinical research of Brilacidin and its multiple target indications (e.g. infectious disease, palliative care, gastrointestinal disease, dermal conditions); Prurisol as a new oral treatment for plaque psoriasis; Kevetrin for solid tumors; and preclinical research being conducted by Cellceutix.  Our comprehensive analysis includes a view of the competitive landscape of drugs marketed and in development by others to deliver an unbiased outlook as to the current and future market opportunity and fair value of the Cellceutix pipeline.

Please contact for Table of Contents